Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast

Novo Nordisk stock dipped Thursday after sales of weight-loss drug, Wegovy, nearly doubled, but missed even more bullish expectations.

Investors Business Daily

Weight-loss Drug Maker Novo Nordisk's Profits Soar Further

The drugmaker increased its market share of the diabetic treatment market by 1.8 percentage points and now has a 34-percent share of the market.

International Business Times

Dow Jones Futures Rise In Stock Market's Day 2 Fed Reaction; Carvana Skyrockets

Futures rose after the stock market erased big Fed-led gains as AI plays such as Nvidia retreated. Carvana soared on earnings.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Breakouts In Focus: Google Goes Wild As Tasty IPO Sets Up

As Google stock gaps up and gets volatile, Novo Nordisk sets up while a hot IPO and leading chipmaker break out.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Investors Business Daily

Dow Jones Futures Rise: Nvidia Leads New Buys; Tesla Runs Past Resistance On Elon Musk Move

Nvidia and several other leaders flashed buy signals as the market roared. Investors should take advantage, but it's a jungle out there.

Investors Business Daily

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Doctors warn unplanned 'Ozempic babies' may be harmed by weight-loss drugs

Women using weight-loss drug semaglutide have reported surprise pregnancies, but doctors warn the risk to babies is not yet clear

Evening Standard

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Persistent shortage of growth hormone frustrates parents and clinicians

As a shortage of growth hormone used to treat rare diseases in children drags on, families and doctors are struggling with insurers' requirements to get prescriptions filled.

WEKU

Albo is right to want to make things in Australia. He’ll just need a bit more cash

It’s a new era of geopolitical competition out there, where old certainties of ‘free trade’ are ending. Australia needs to pivot — will Albanese’s policy be enough?

Crikey

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

Shark Tank's Mark Cuban speaks out on weight-loss drugs

A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisk's Ozempic to something new from Eli Lilly.

The Street

3 Best Mega-Cap Stocks for Dividend Investors

Discover the compelling stories behind three mega-cap dividend stocks that have caught the attention of analysts and investors alike.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Ozempic success story: 'Weight-loss drugs, costs and my health'

Ozempic is pricey, but a great health insurance plan paved the way for a software professional to experience dramatic results.

StockNews.com

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Investors Business Daily

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

The Street

Costco enters a controversial industry with its latest move

The retail giant is expanding one of its beloved programs to include a growing trend.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Ozempic, weight-loss drugs force a change of focus on health

The effectiveness of weight-loss drugs mean people who take them have more fitness challenges to confront.

The Street

Ozempic, weight-loss drugs rise and the fitness industry reacts

The increasing popularity of GLP-1 medications such as Ozempic triggers some changes.

The Guardian - UK

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

Investors Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Barchart

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Investors Business Daily

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

1 … 5 6 7 8

People

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.